Peru-15, an improved live attenuated oral vaccine candidate for vibrio cholerae O1

Julie R. Kenner, Trinka S. Coster, David N. Taylor, Andrew F. Trofa, Maria Barrera-Oro, Tracy Hyman, Jennifer M. Adams, David T. Beattie, Kevin P. Killeen, Dale R. Spriggs, John J. Mekalanos, Jerald C. Sadoff

Research output: Contribution to journalArticlepeer-review

Abstract

Cholera vaccine candidate Peru-15 was derived from a Vibrio cholerae O1 E1 Tor Inaba strain by deleting the cholera toxin genetic element, introducing the gene encoding cholera toxin B subunit into recA, and screening for nonmotility. In a controlled study, Peru-15 (2 × 108cfu) was administered to 11volunteers. No vaccinee developed diarrhea, and 10 of 11 had =4-fold rises in vibriocidal antibody titers. One month later, 5 vaccinees and 5 control volunteers were challenged with wild type V. cholerae O1. Four of 5 controls developed diarrhea (mean, 1.9 L). Two Peru-15 vaccinees developed diarrhea, 1 with <0.3 L and 1 with ∼1.0 L; this latter volunteer had not developed a significant vibriocidalimmune response to vaccination. Peru-15 shows promise as a single-dose, oral cholera vaccine that is safe, immunogenic, and protective.

Original languageEnglish (US)
Pages (from-to)1126-1129
Number of pages4
JournalJournal of Infectious Diseases
Volume172
Issue number4
DOIs
StatePublished - Oct 1995
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Peru-15, an improved live attenuated oral vaccine candidate for vibrio cholerae O1'. Together they form a unique fingerprint.

Cite this